IP Library › Granted Patent US 11,840,735
Granted Patent B2
US 11,840,735 · App. 16/518,783 · Granted Dec 12, 2023

Methods and materials for identifying malignant skin lesions

Inventors: Alexander Meves (Rochester, MN); Ekaterina M. Nikolova (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
C12Q1/6886C12Q2600/112C12Q2600/158C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,840,735
App. No.
16/518,783
Granted
Dec 12, 2023
Kind
B2
Abstract

This document provides methods and materials for identifying malignant skin lesions (e.g., malignant pigmented skin lesions). For example, methods and materials for using quantitative PCR results and correction protocols to reduce the impact of basal keratinocyte contamination on the analysis of test sample results to identify malignant skin lesions are provided.

Claims (13)

1. A set of kit components within a kit for identifying a malignant skin lesion in a subject when used together with a set of reagents comprising:

(a) primer pairs for determining, within a test sample taken from the subject, the expression level of marker genes PLAT, ITGB3, and IL8 to obtain a measured expression level of the marker genes for the test sample, and

(b) a primer pair for determining, within the test sample, the expression level of marker gene GDF15, to obtain a measured expression level of the marker gene GDF15 for the test sample,

wherein the set of kit components comprises:

a control nucleic acid for each of the primer pairs,

wherein each control nucleic acid comprises a target nucleic acid for one of the primer pairs configured to obtain a standard curve for the primer pair, and

wherein each of the control nucleic acids is complementary DNA (cDNA) specific for cDNA and not specific for genomic DNA.

2. A set of kit components within a kit comprising:

(i) a first composition comprising a control nucleic acid for a primer pair for determining, within a test sample, the expression level of marker gene GDF15, said control nucleic acid comprising a target nucleic acid for the primer pair configured to obtain a standard curve for the primer pair;

(ii) a second composition comprising a control nucleic acid for a primer pair for determining, within the test sample, the expression level of marker gene PLAT, said control nucleic acid comprising a target nucleic acid for the primer pair configured to obtain a standard curve for the primer pair;

(iii) a third composition comprising a control nucleic acid for a primer pair for determining, within the test sample, the expression level of marker gene ITGB3, said control nucleic acid comprising a target nucleic acid for the primer pair configured to obtain a standard curve for the primer pair; and

(iv) a fourth composition comprising a control nucleic acid for a primer pair for determining, within the test sample, the expression level of marker gene IL8, said control nucleic acid comprising a target nucleic acid for the primer pair configured to obtain a standard curve for the primer pair,

wherein each of the control nucleic acids is complementary DNA (cDNA) specific for cDNA and not specific for genomic DNA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2021
From: MEVES, ALEXANDER; NIKOLOVA, EKATERINA M.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 056841/0397 →
Continuity (3)
Continuation 14442673
Provisional Application 61726217 · Nov 14, 2012
Related Publication 20190338372A1 · Nov 7, 2019